JPWO2022105852A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022105852A5 JPWO2022105852A5 JP2023530323A JP2023530323A JPWO2022105852A5 JP WO2022105852 A5 JPWO2022105852 A5 JP WO2022105852A5 JP 2023530323 A JP2023530323 A JP 2023530323A JP 2023530323 A JP2023530323 A JP 2023530323A JP WO2022105852 A5 JPWO2022105852 A5 JP WO2022105852A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- membered
- pharma
- general formula
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- -1 cyano, amino Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 206010014664 Endocardial fibrosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000023281 Fallot tetralogy Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 229940122960 Myosin inhibitor Drugs 0.000 claims 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011310827.4 | 2020-11-20 | ||
| CN202011310827 | 2020-11-20 | ||
| CN202110021509.4 | 2021-01-08 | ||
| CN202110021509 | 2021-01-08 | ||
| CN202110244090 | 2021-03-05 | ||
| CN202110244090.9 | 2021-03-05 | ||
| CN202110464375 | 2021-04-28 | ||
| CN202110464375.3 | 2021-04-28 | ||
| PCT/CN2021/131642 WO2022105852A1 (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550444A JP2023550444A (ja) | 2023-12-01 |
| JPWO2022105852A5 true JPWO2022105852A5 (da) | 2024-05-23 |
Family
ID=81708401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530323A Pending JP2023550444A (ja) | 2020-11-20 | 2021-11-19 | トリアジンジオン系誘導体、その調製方法及びその医薬的応用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010639A1 (da) |
| EP (1) | EP4249474A4 (da) |
| JP (1) | JP2023550444A (da) |
| KR (1) | KR20230110538A (da) |
| CN (1) | CN116323598A (da) |
| AU (1) | AU2021381664A1 (da) |
| CA (1) | CA3198934A1 (da) |
| MX (1) | MX2023005533A (da) |
| TW (1) | TW202227420A (da) |
| WO (1) | WO2022105852A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| KR20230158532A (ko) * | 2021-03-17 | 2023-11-20 | 한서 바이오 엘엘씨 | 질소-함유 헤테로사이클릭 케톤, 이의 제조방법 및 의학적 용도 |
| WO2023222103A1 (zh) * | 2022-05-20 | 2023-11-23 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的晶型及制备方法 |
| TW202416997A (zh) * | 2022-09-16 | 2024-05-01 | 大陸商江蘇豪森藥業集團有限公司 | 一種含氮雜環酮化合物的晶型及其製備方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117929C2 (uk) * | 2013-06-21 | 2018-10-25 | Міокардіа, Інк. | Сполуки піримідиндіону, спрямовані проти станів серцево-судинної системи |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9663516B2 (en) * | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| MX2018016331A (es) | 2016-06-20 | 2019-05-20 | Novartis Ag | Formas cristalinas de compuesto de triazolopirimidina. |
| SG11201912166XA (en) | 2017-07-24 | 2020-02-27 | Novartis Inflammasome Research Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| CN111182901A (zh) | 2017-08-04 | 2020-05-19 | 迈奥卡迪亚公司 | 用于在肥厚型心肌病的治疗中使用的玛伐凯泰 |
| WO2019149205A1 (zh) * | 2018-01-31 | 2019-08-08 | 江苏恒瑞医药股份有限公司 | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| KR20210068422A (ko) * | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| US11034693B2 (en) | 2018-10-29 | 2021-06-15 | MyoKardia, Inc. | Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases |
| WO2020151605A1 (zh) * | 2019-01-25 | 2020-07-30 | 青岛吉澳医药科技有限公司 | 氘代苯甲氨嘧啶二酮衍生物及其用途 |
| CN110698415B (zh) | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
-
2021
- 2021-11-19 AU AU2021381664A patent/AU2021381664A1/en active Pending
- 2021-11-19 CN CN202180065655.5A patent/CN116323598A/zh active Pending
- 2021-11-19 EP EP21893999.9A patent/EP4249474A4/en active Pending
- 2021-11-19 TW TW110143208A patent/TW202227420A/zh unknown
- 2021-11-19 WO PCT/CN2021/131642 patent/WO2022105852A1/zh active Application Filing
- 2021-11-19 KR KR1020237019549A patent/KR20230110538A/ko active Search and Examination
- 2021-11-19 JP JP2023530323A patent/JP2023550444A/ja active Pending
- 2021-11-19 MX MX2023005533A patent/MX2023005533A/es unknown
- 2021-11-19 US US18/253,704 patent/US20240010639A1/en active Pending
- 2021-11-19 CA CA3198934A patent/CA3198934A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK170891B1 (da) | 1,4-dihydropyridin-3,5-dicarboxylsyrederivater og fremgangsmåde til fremstilling deraf samt farmaceutisk middel indeholdende dem | |
| JP6444866B2 (ja) | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン及びその医薬として許容し得る形態の製造プロセス | |
| JP2009544620A (ja) | 自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト | |
| JP2007507542A5 (da) | ||
| JPWO2020103815A5 (da) | ||
| CA2626402A1 (en) | Potassium channel inhibitors | |
| EP1302463A1 (en) | Medicine comprising dicyanopyridine derivative | |
| JP2010501587A5 (da) | ||
| JPH0789958A (ja) | ４−アミノピリミジン誘導体、その製造方法およびそれを含有する医薬品 | |
| DK2059503T3 (da) | Aminopyrazolderivater, fremgangsmåde til fremstilling deraf, og sammensætning indeholdende disse derivater til forebyggelse eller behandling af iskæmiske sygdomme | |
| JP2006507355A5 (da) | ||
| CN110357789B (zh) | 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途 | |
| JP2018529690A5 (da) | ||
| IL269835B (en) | Novel dual-acting soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses | |
| JPS59118783A (ja) | 新規の置換された１，４−ジヒドロピリジン、その製造法及びこれを診断剤として使用する方法 | |
| FR2562892A1 (fr) | Nouveaux dihydropyridinyldicarboxylates amides et esters, utilisation de ces composes comme medicament, compositions pharmaceutiques comprenant de tels composes et procede pour la preparation de tels composes | |
| JPH05213879A (ja) | 新規（２‐アルキル‐３‐ピリジル）メチルピペラジン誘導体 | |
| HUE030696T2 (en) | Process for the preparation of dabigatran etexilate and its intermediates | |
| JPWO2022105852A5 (da) | ||
| FR2566404A1 (fr) | Nouveaux derives de la 1,4-dihydropyridine, leurs sels, procede pour les preparer, et compositions pharmaceutiques les contenant | |
| JP2004505079A (ja) | アリールアセチルアミノチアゾール化合物の製造法 | |
| HUT70534A (en) | 2-amino-4-quinoline-dihydropyridines, process for producing them and their use for producing pharmaceutical compositions | |
| LU84797A1 (fr) | Dihydropyridylimidates cycliques | |
| JPH0629244B2 (ja) | １，４−ジヒドロピリジン誘導体 | |
| JPWO2020005887A5 (da) |